A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab in Patients With Advanced Lung Cancer
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Tifcemalimab (Primary) ; Toripalimab (Primary)
- Indications Lung cancer; Non-small cell lung cancer; Small cell lung cancer
- Focus Adverse reactions
- Sponsors Shanghai Junshi Biosciences
- 06 Jun 2023 Results (As of 31 Jan 2023; n=43) presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 05 Sep 2021 Status changed from not yet recruiting to recruiting.
- 19 Aug 2021 New trial record